Glioblastoma Multiforme Market Report 2026

The glioblastoma multiforme market size has grown strongly in recent years. It will grow from $2.7 billion in 2025 to $2.92 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to limited treatment options, advancements in neuro-oncology, chemotherapy standardization, growth of cancer research centers, improved imaging technologies.

The glioblastoma multiforme market size is expected to see strong growth in the next few years. It will grow to $3.94 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to development of novel targeted drugs, expansion of immunotherapy research, personalized cancer treatment adoption, increased funding for brain cancer research, improved survival outcome focus. Major trends in the forecast period include increased focus on targeted cancer therapies, rising use of multimodal treatment approaches, expansion of precision oncology research, growing adoption of advanced imaging diagnostics, improved clinical trial participation.

The rising cases of brain disorders are expected to drive the glioblastoma multiforme market in the coming years. Brain disorders are conditions that affect the structure or function of the brain, resulting in cognitive, emotional, or physical impairments. The increase in brain disorder cases is attributed to factors such as aging populations, longer life expectancy, lifestyle factors, and enhanced diagnostic capabilities. Understanding brain disorders supports advancements in glioblastoma multiforme (GBM) research, enabling earlier detection, innovative treatments, and improved patient outcomes. By studying neurological conditions, researchers can identify genetic and molecular mechanisms that contribute to GBM development. For instance, in February 2025, Dementia Australia, a non-profit organization, reported that approximately 433,300 Australians are living with dementia, with this number projected to reach 812,500 by 2054. Additionally, younger-onset dementia affects around 29,000 people in 2025, with projections increasing to 41,000 by 2054. Therefore, the rising prevalence of brain disorders is driving the growth of the glioblastoma multiforme market.

Major companies in the glioblastoma multiforme market are focusing on advanced therapies, such as CAR T-cell therapies, to address the unmet needs in treating aggressive cancers. CAR T-cell therapies are a type of immunotherapy that involves modifying a patient’s T-cells to specifically target and eliminate cancer cells more effectively. For instance, in June 2023, Chimeric Therapeutics Limited, an Australia-based biotech company, initiated a Phase IB clinical trial of CHM 1101 (CLXT CAR T) therapy for recurrent or progressive glioblastoma multiforme (GBM). Conducted across multiple centers, the trial aims to assess the therapy’s safety and efficacy while determining the recommended Phase 2 dose. Initial Phase 1a results indicated disease stability, and the trial is intended to generate data to support the design of a registration trial and regulatory feedback.

In October 2024, Merck & Co., a US-based pharmaceutical company specializing in prescription medicines and vaccines, acquired Modifi Biosciences for an undisclosed amount. Through this acquisition, Merck aims to strengthen its oncology pipeline by incorporating Modifi’s preclinical small-molecule platform, which targets cancer cells with defects in DNA repair, including those lacking the O6-methylguanine-DNA methyltransferase (MGMT) protein, and demonstrates potential against highly refractory tumors such as glioblastoma. Modifi Biosciences Inc. is a US-based company focused on developing treatments for glioblastoma multiforme (GBM).

Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.

North America was the largest region in the glioblastoma multiforme market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glioblastoma multiforme market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the glioblastoma multiforme market by increasing costs of imported oncology drugs, imaging equipment, and diagnostic reagents. Hospitals and cancer treatment centers are most affected due to reliance on imported therapies. These tariffs increase treatment costs by raising expenses for chemotherapy, imaging-based monitoring, and molecular diagnostics. However, they encourage domestic oncology drug development, supporting local innovation in cancer therapeutics.

The glioblastoma multiforme market research report is one of a series of new reports that provides glioblastoma multiforme market statistics, including glioblastoma multiforme industry global market size, regional shares, competitors with a glioblastoma multiforme market share, detailed glioblastoma multiforme market segments, market trends and opportunities, and any further data you may need to thrive in the glioblastoma multiforme industry. This glioblastoma multiforme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Glioblastoma multiforme (GBM) is an aggressive, fast-growing brain tumor that arises from the glial cells of the brain. It is a highly lethal form of primary brain cancer, marked by rapid cell proliferation and resistance to standard treatments.

The main drug classes for glioblastoma multiforme include chemotherapy agents, temozolomide, carmustine, lomustine, and others. Chemotherapy agents work by targeting and disrupting cancer cell division, helping to control tumor growth and improve survival, often in combination with other therapies. Diagnosis is made using various tools such as magnetic resonance imaging (MRI), computed tomography (CT) scans, biopsies, and others. Treatment options include surgery, radiation therapy, chemotherapy, immunotherapy, tumor treating field therapy, and more. These treatments are utilized by a range of end users, including hospitals, cancer research institutes, ambulatory surgical centers, and others.

The glioblastoma multiforme market consists of revenues earned by entities by providing services such as palliative care, psychosocial support, and rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The glioblastoma multiforme market also includes sales of drugs, diagnostic tools, personalized medicine, and advanced drug delivery systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.